Anterior cervical discectomy and fusion (or ACDF) surgery serves to remove herniated or degenerative spinal discs. A discectomy literally “cuts out the disc” anywhere along the spine from the neck to the low back. Along this procedure, different devices can be inserted to restore patient’s motion: Interbody fusion cage “Anterior cervical discectomy” has matured into a …
Cerebral palsy is the most common cause of physical disability in children, and there is no cure. Umbilical cord blood (UCB) cell therapy for the treatment of children with cerebral palsy is currently being assessed in clinical trials. Although there is much interest in the use of UCB stem cells for neuroprotection and neuroregeneration, the mechanisms of action are not fully understood. Further, UCB contains many stem and progenitor cells of interest, and we will point out that individual cell types within UCB may elicit specific effects. UCB is a clinically proven source of hemotopoietic stem cells (HSCs). It also contains mesenchymal stromal cells (MSCs), endothelial progenitor cells (EPCs), and immunosupressive cells such as regulatory T cells (Tregs) and monocyte-derived supressor cells.
Autism spectrum disorders (ASDs) are characterized by core domains: persistent deficits in social communication and interaction; restricted, repetitive patterns of behavior, interests, or activities. ASDs comprise heterogeneous and complex neurodevelopmental pathologies with well-defined inflammatory conditions and immune system dysfunction.
Cell-based therapies hold significant promise for infants at risk for cerebral palsy (CP) from perinatal brain injury (PBI). PBI leading to CP results from multifaceted damage to neural cells. Complex developing neural networks are injured by neural cell damage plus unique perturbations in cell signaling. Given that cell-based therapies can simultaneously repair multiple injured neural …
You will have to log in or register to view the full content. Degenerative disc disease (DDD) induces chronic back pain with limited nonsurgical options. In this open label pilot study, 26 patients (median age 40 years; range 18–61) received autologous bone marrow concentrate (BMC) disc injections (13 one level, 13 two levels). Pretreatment Oswestry disability index (ODI) and visual analog scale (VAS) were performed to establish baseline pain scores (average 56.5 and 79.3, respectively), while magnetic resonance imaging was independently scored according to the modified Pfirrmann scale.
Cell therapies hold significant promise for the treatment of injured or diseased musculoskeletal tissues. However, despite advances in research, there is growing concern about the increasing number of clinical centres around the world that are making unwarranted claims or are performing risky biological procedures. Such providers have been known to recommend, prescribe, or deliver so called ‘stem cell’ preparations without sufficient data to support their true content and efficacy. You will have to log in or register to view the full content.
You will have to log in or register to view the full content. The direct and indirect costs of treating pathology related to discogenic back pain in the United States exceed $100 billion annually [1, 2]. The development of disc degeneration in the lumbar spine is almost universal over the age of 50 years. This observation appears related to humans’ recent evolution to an upright posture and S-shaped spinal column [3–6].
Lumbar radiculopathy is commonly known as “Sciatica”. It is a relatively common condition affecting an estimated 12-40% of patients who are suffering from low back pain.
Stem cell therapy is a novel therapy to consider in these patients. Radiculopathy by definition means inflammation of the nerve. Stem cells are known to secrete very potent anti-inflammatory proteins and thus relieve inflammation and pain. Thus it seems logical to use stem cells to treat the inflammation of the nerves.
“Stem cell tourism” is defined as the unethical practice of offering unproven cellular preparations to patients suffering from various medical conditions. This phenomenon is rising in the field of neurology as patients are requesting information and opportunities for treatment with stem cells for incurable conditions such as multiple sclerosis and amyotrophic lateral sclerosis, despite their clinical research and experimental designation. Here, we review the recent trends in “stem cell tourism” in both the United States and abroad, and discuss the recent reports of neurological complications from these activities. Finally, we frame critical questions for the field of neurology regarding training in the ethical, legal, and societal issues of the global “stem cell tourism,” as well as suggest strategies to alleviate this problem.
What happens when a precise stem cell injection is used instead of surgery to treat spondylolysis? This is the story of NH, an Ivy League wrestler whose career was stopped in its tracks by a traumatic fracture of the spine called spondylolysis. His parents knew that fusing this young man’s spine at his young age was a bad idea, so they began to research spondylolysis treatment options and eventually made their way to our Colorado clinic. Thankfully, at about two months following his stem cell procedure, NH appears to be on his way toward healing this fracture by harnessing the power of his own body rather than using plates and screws. You will have to log in or register to view the full content.